EU proposes GDP revisions to factor in falsified medicines directive and other advancements
This article was originally published in SRA
The European Commission has proposed major amendments to its guidance on good distribution practices for human medicines to take into account the legislative changes introduced by the new EU directive on falsified medicines and distribution practice advancements in general1-3.
You may also be interested in...
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.